Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Gains from Investment Securities (2016 - 2025)

Rein Therapeutics filings provide 10 years of Gains from Investment Securities readings, the most recent being $87500.0 for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities fell 64.87% year-over-year to $87500.0, compared with a TTM value of $18000.0 through Dec 2025, up 80.0%, and an annual FY2025 reading of $59310.0, down 98.13% over the prior year.
  • Gains from Investment Securities hit $87500.0 in Q3 2025 for Rein Therapeutics, up from $18000.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $11.1 million in Q2 2022, with the low at $10000.0 in Q4 2023.
  • Median Gains from Investment Securities over the past 5 years was $1.7 million (2022), compared with a mean of $3.8 million.
  • The sharpest move saw Gains from Investment Securities soared 105.09% in 2021, then plummeted 66.47% in 2022.
  • Year by year, Gains from Investment Securities stood at $9.4 million in 2021, then tumbled by 66.47% to $3.1 million in 2022, then plummeted by 99.68% to $10000.0 in 2023, then surged by 2390.75% to $249075.0 in 2024, then tumbled by 64.87% to $87500.0 in 2025.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at $87500.0, $18000.0, and $249075.0 for Q3 2025, Q1 2025, and Q3 2024 respectively.